DFDaryl Michal Freedman

Daryl Michal Freedman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daryl Michal Freedman has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Martha S. Linet

    5 shared publications
  • Elizabeth K. Cahoon

    3 shared publications
  • Jincao Wu

    Department of Health and Human Services, National Institutes of Health, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland

    3 shared publications
  • Ralph W. Kuncl

    Department of Biology, University of Redlands, Redlands, California

    3 shared publications
  • Ruth M. Pfeiffer

    Department of Health and Human Services, National Institutes of Health, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland

    3 shared publications
  • Bruce H. Alexander

    Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, MN, USA

    2 shared publications

Latest Publications

  • Relationship between plasma 25-hydroxymitamin D and leucocyte telomere length by sex and race in a US study – CORRIGENDUM

    by Jason J. Liu, Elizabeth K. Cahoon, Martha S. Linet, Mark P. Little, Casey L. Dagnall, Herbert Higson, Sharon A. Savage, D. Michal Freedman

  • Open Access

    Associations between cancer and Alzheimer's disease in a U.S. Medicare population

    by Daryl Michal Freedman, Jincao Wu, Honglei Chen, Ralph W. Kuncl, Lindsey R. Enewold, Eric A. Engels, Neal D. Freedman, Ruth M. Pfeiffer

    Several studies have reported bidirectional inverse associations between cancer and Alzheimer's disease (AD). This study evaluates these relationships in a Medicare population. Using Surveillance, Epidemiology, and End Results (SEER) linked to Medicare data, 1992–2005, we evaluated cancer risks following AD in a case–control study of 836,947 cancer cases and 142,869 controls as well as AD risk after cancer in 742,809 cancer patients and a non‐cancer group of 420,518. We applied unconditional logistic regression to estimate odds ratios (ORs) and Cox proportional hazards models to estimate hazards ratios (HRs). We also evaluated cancer in relation to automobile injuries as a negative control to explore potential study biases. In the case–control analysis, cancer cases were less likely to have a prior diagnosis of AD than controls (OR = 0.86; 95% CI = 0.81–0.92). Cancer cases were also less likely than controls to have prior injuries from automobile accidents to the same degree (OR = 0.83; 95% CI = 0.78–0.88). In the prospective cohort, there was a lower risk observed in cancer survivors, HR = 0.87 (95% CI = 0.84–0.90). In contrast, there was no association between cancer diagnosis and subsequent automobile accident injuries (HR = 1.03; 95% CI = 0.98–1.07). That cancer risks were similarly reduced after both AD and automobile injuries suggest biases against detecting cancer in persons with unrelated medical conditions. The modestly lower AD risk in cancer survivors may reflect underdiagnosis of AD in those with a serious illness. This study does not support a relationship between cancer and AD.


  • Open Access

    Relationship between plasma 25-hydroxyvitamin D and leucocyte telomere length by sex and race in a US study

    by Jason J. Liu, Elizabeth K. Cahoon, Martha S. Linet, Mark P. Little, Casey L. Dagnall, Herbert Higson, Sharon A. Savage, D. Michal Freedman

    A few studies have examined the association between vitamin D and telomere length, and fewer still have examined the relationship in black or male populations. We investigated the cross-sectional association between the vitamin D metabolite 25-hydroxyvitamin D (25(OH)D) concentration in plasma and relative leucocyte telomere length (LTL) in 1154 US radiologic technologists who were 48–93 years old (373 white females, 278 white males, 338 black females, 165 black males). Plasma 25(OH)D concentration was measured by the chemiluminescence immunoassay, and relative LTL was measured by quantitative PCR. Logistic regression was used to obtain OR and 95 % CI for long v. short (based on median) LTL in relation to continuous 25(OH)D, quartiles of 25(OH)D and 25(OH)D deficiency. We found no significant association between continuous 25(OH)D and long LTL in all participants (Ptrend=0·440), nor in white females (Ptrend=0·845), white males (Ptrend=0·636), black females (Ptrend=0·967) or black males (Ptrend=0·484). Vitamin D deficiency (defined as 25(OH)DP=0·024), but not in other groups. In this population, we found little evidence to support associations between 25(OH)D and long LTL over the entire range of 25(OH)D in the overall study population or by sex and race.


  • Open Access

    Associations Between Parkinson Disease and Cancer in US Asian Americans

    by D. Michal Freedman, Ruth M. Pfeiffer

    Epidemiologic studies1-3 of the association between cancer and Parkinson disease (PD) have generally found a lower risk of cancer after PD and vice versa. Most studies1-3 have examined primarily white or Western populations. In contrast, Lin et al4 analyzed a Taiwanese population and found elevated risks for total and most cancer sites after PD. They attributed the elevated risks to ethnicity or environmental exposures. In a comment5 on the article by Lin et al,4 we suggested that the authors examine whether medical surveillance contributed to the risks.


  • Open Access

    Associations between cancer and Parkinson’s disease in U.S. elderly adults

    by D Michal Freedman, Jincao Wu, Honglei Chen, Eric A Engels, Lindsey R Enewold, Neal D Freedman, James J Goedert, Ralph W Kuncl, Mitchell H Gail, Ruth M Pfeiffer

    Background: Several studies suggest that cancer is reduced before and after a Parkinson’s disease (PD) diagnosis. However, determining relationships among diseases of ageing is challenging due to possible biases in ascertaining disease. This study evaluates the PD and cancer relationship, addressing potential biases. Methods: Using Surveillance, Epidemiology, and End Results-Medicare linked data (1992–2005) of adults ≥ 65 years, we assessed PD risk after cancer comparing PD in 743 779 cancer patients with PD in a non-cancer group ( n = 419 432) in prospective cohort analyses. We also conducted a case-control study of 836 947 cancer cases and 142 869 controls to assess cancer following PD. We applied Cox proportional hazards models to estimate hazards ratios (HRs) for PD after cancer and unconditional logistic regression to estimate odds ratios (ORs) for PD preceding cancer, controlling for physician visits and other factors. To explore biases in ascertaining cancer, we examined relationships between cancer and automobile accident injuries, which we expected to be null. Results: No association was observed between cancer and subsequent PD [HR = 0.97; 95% confidence interval (CI) = 0.92-1.01] nor between cancer and subsequent automobile injuries (HR = 1.03; 95% CI = 0.98-1.07). One site, lung cancer, was associated with subsequent reduced PD, which may reflect confounding by smoking. In the case-control analysis, PD was associated with reduced subsequent cancer, overall (OR = 0.77; 95% CI = 0.71-0.82) and for several cancer sites. However, the automobile injury/ subsequent cancer association was similar (OR = 0.83; 95% CI = 0.78-0.88), suggesting a cancer detection bias after serious health outcomes. Conclusions: In totality, our data do not support a biological relationship between PD and cancer.


  • Ambient temperature and risk of first primary basal cell carcinoma: A nationwide United States cohort study

    by D. Michal Freedman, Cari M. Kitahara, Martha S. Linet, Bruce H. Alexander, Gila Neta, Mark P. Little, Elizabeth K. Cahoon


  • Open Access

    The risk of amyotrophic lateral sclerosis after cancer in U.S. elderly adults: A population‐based prospective study

    by D. Michal Freedman, Jincao Wu, Sarah E. Daugherty, Ralph W. Kuncl, Lindsey R. Enewold, Ruth M. Pfeiffer

    Although epidemiologic studies have examined the risk of amyotrophic lateral sclerosis (ALS) in relation to cancer, none have been large population‐based studies using incident ALS and adjusting for medical surveillance. Addressing those limitations, all first primary cancer cases from the Surveillance, Epidemiology and End Results (SEER) Program (1992–2005), linked to Medicare claims data were used. Cases were followed from cancer diagnosis until the earliest date of ALS diagnosis, a break in Medicare claims data, death, age 85 or December 31, 2005. A comparison group from a 5% random Medicare sample in the SEER areas who were cancer‐free and censored as above, or until a cancer diagnosis were selected. ALS outcomes were derived from medical claims. The proportional hazards models to estimate ALS hazard ratios (HRs), using age as the time scale, adjusting for sex, race and physician visits, and stratifying the baseline hazard on birth year and SEER registry were used. A total of 303 ALS cases were ascertained in cancer patients (2,154,062 person‐years) compared with 246 ALS cases (2,467,634 person‐years) in the reference population. There was no overall relationship between cancer and ALS (HR = 0.99; 95% CI = 0.81–1.22), nor by gender or race. Except for an elevated ALS risk in the first year after a leukemia diagnosis, the relationship between site‐specific cancers and ALS was null after correcting for multiple comparisons. Having a cancer diagnosis was not associated with an overall risk of incident ALS. The short‐term ALS risk after leukemia may reflect screening or reporting errors.


  • Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis

    by D. Michal Freedman, Ralph W. Kuncl, Stephanie J. Weinstein, Nea Malila, Jarmo Virtamo, Demetrius Albanes

    There are no observational studies or controlled trials of amyotrophic lateral sclerosis (ALS) and circulating α-tocopherol (vitamin E) for prevention of ALS. This study addresses that gap. The study population comprised 29,127 Finnish male smokers, aged 50−69 years, who participated in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, which is both a prospective cohort and a randomized, double-blind, placebo-controlled trial of α-tocopherol (50 mg/day) and β-carotene (20 mg/day). Serum α-tocopherol and β-carotene was assayed at baseline (1985 − 1988). Follow-up (median 16.7 years) continued through 2004. ALS cases were identified through the national Hospital Discharge Register with diagnostic verification by hospital records and death certificates. During 407,260 person-years of follow-up, 50 men were identified with ALS. For males with serum α-tocopherol concentration above the median (≥ 11.6 mg/l), the age-adjusted relative risk (RR) compared to α-tocopherol below the median, was 0.56 (95% confidence interval 0.32 − 0.99), p = 0.046. The RR among α-tocopherol supplement recipients was 0.75 (95% CI 0.32 − 1.79), p = 0.52. Neither serum β-carotene level nor β-carotene supplementation was associated with ALS. In conclusion, the results are consistent with a hypothesized protective effect of α-tocopherol on ALS risk. However, pooled analyses of cohorts with serum and controlled trials are needed to clarify the role of α-tocopherol in ALS risk.


  • The association between cancer and amyotrophic lateral sclerosis

    by D. Michal Freedman, Rochelle E. Curtis, Sarah E. Daugherty, James J. Goedert, Ralph W. Kuncl, Margaret A. Tucker

    Objective Increasing evidence suggests that some neurodegenerative disorders, such as Parkinson’s disease, are inversely related to cancer. Few epidemiologic studies have examined the relationship between cancer and amyotrophic lateral sclerosis (ALS), another major neurodegenerative disease. This study addresses that gap. Methods Using data from 16 population-based cancer registries of the Surveillance, Epidemiology, and End Results (SEER) Program of the U.S. National Cancer Institute and death certificates, we followed 2.7 million cancer survivors who were diagnosed between 1973 and 2007, and who survived at least 1 year following cancer diagnosis. The standardized mortality ratio (SMR) of observed to expected ALS deaths in cancer survivors was calculated. Results A total of 1,216 ALS deaths were reported among 1 year survivors of cancer over 16.6 million person-years of follow-up. ALS mortality was not significantly associated with the incidence of total cancers [SMR = 1.00 (95 % confidence interval (CI), 0.95–1.06)]. There was, however, a significantly elevated risk of ALS death among survivors of melanoma [SMR = 1.49 (95 % (CI), 1.17–1.85)] and of tongue cancer [SMR = 2.57 (95 % CI, 1.41–4.32)], and a significantly reduced ALS death risk among prostate cancer survivors [SMR = 0.86 (95 % CI, 0.76–0.96)]. Conclusions Cancer at certain sites may be related to risk of ALS death. Possible biologic factors linking ALS to these cancers are discussed. Future studies should attempt to confirm these associations using incident ALS outcomes. Establishing relationships between cancer and neurodegenerative diseases, such as ALS, opens new opportunities for understanding related pathophysiologic and therapeutic possibilities for these diseases.


  • Open Access

    Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study

    by Roger L Milne, Mia M Gaudet, Amanda B Spurdle, Peter A Fasching, Fergus J Couch, Javier Benítez, José Ignacio Arias Pérez, M Pilar Zamora, Núria Malats, Isabel dos Santos Silva, et al.

    Introduction: Several common breast cancer genetic susceptibility variants have recently been identified. We aimed to determine how these variants combine with a subset of other known risk factors to influence breast cancer risk in white women of European ancestry using case-control studies participating in the Breast Cancer Association Consortium. Methods: We evaluated two-way interactions between each of age at menarche, ever having had a live birth, number of live births, age at first birth and body mass index (BMI) and each of 12 single nucleotide polymorphisms (SNPs) (10q26-rs2981582 (FGFR2), 8q24-rs13281615, 11p15-rs3817198 (LSP1), 5q11-rs889312 (MAP3K1), 16q12-rs3803662 (TOX3), 2q35-rs13387042, 5p12-rs10941679 (MRPS30), 17q23-rs6504950 (COX11), 3p24-rs4973768 (SLC4A7), CASP8-rs17468277, TGFB1-rs1982073 and ESR1-rs3020314). Interactions were tested for by fitting logistic regression models including per-allele and linear trend main effects for SNPs and risk factors, respectively, and single-parameter interaction terms for linear departure from independent multiplicative effects. Results: These analyses were applied to data for up to 26,349 invasive breast cancer cases and up to 32,208 controls from 21 case-control studies. No statistical evidence of interaction was observed beyond that expected by chance. Analyses were repeated using data from 11 population-based studies, and results were very similar. Conclusions: The relative risks for breast cancer associated with the common susceptibility variants identified to date do not appear to vary across women with different reproductive histories or body mass index (BMI). The assumption of multiplicative combined effects for these established genetic and other risk factors in risk prediction models appears justified.